The inhibition of nuclear factor kappa B (NF-jB) by, for instance, curcumin is becoming an important new approach in combination with chemotherapy or irradiation for the treatment of a variety of cancers including haematological malignancies. A dose-limiting side effect of anticancer therapy in the gastrointestinal tract is mucosal barrier injury. It is hypothesised that mucosal barrier injury is initiated and amplified by proinflammatory-and NF-jB-regulated mediators. Therefore, the effect of NF-jB inhibition was studied in the onset of mucosal barrier injury. In response to cytostatic drug treatment (arabinoside cytosine (Ara-C) and methotrexate (MTX)), NF-jB was activated in intestinal epithelial cells (IEC-6) resulting in an NF-jB-related induction of tumour necrosis factor alpha and monocyte chemoattractant protein-1. NF-jB inhibition increased the susceptibility of IEC-6 cells to Ara-C as well as MTX-induced cell death when obtained by the addition of caffeic acid phenethyl ester (CAPE), but not using curcumin. In an animal model for MTX-induced mucosal barrier injury, the induction of NF-jB-related cytokines and chemokines was detected upon treatment with MTX. Despite increased susceptibility shown in vitro, the inhibition of NF-jB resulted in a partial amelioration of villous atrophy normally seen in the small intestine upon MTX treatment. These results show that the inhibition of NF-jB does not increase intestinal side effects of the anticancer treatment, suggesting a safe use of curcumin and CAPE in combination with anticancer treatment.
Introduction
Targeting nuclear factor kappa B (NF-kB) is a promising new approach to treat a variety of cancers including haematological malignancies; this in combination with chemotherapy or irradiation. NF-kB is a ubiquitous transcription factor that regulates the transcription of many genes involved in immune and inflammatory responses as well as cell survival. 1 In nonstimulated cells, NF-kB is localised in the cytoplasm associated with inhibitory proteins of the inhibitor kB (IkB) family, rendering NF-kB inactive. The best understood pathway of NF-kB activation is the activation by IkB kinases. 2, 3 In response to multiple activating signals, IkB is phosphorylated, and subsequently ubiquitinated. This ubiquitination leads to rapid proteasomal degradation of IkB, unmasking the nuclear localisation signal of NF-kB. NF-kB is subsequently translocated into the nucleus, resulting in the activation and transcription of several genes. [4] [5] [6] Transcription of both proinflammatory protein tumour necrosis factor alpha (TNF-a) as well as chemokine monocyte chemoattractant protein (MCP-1) is regulated by NF-kB. 7, 8 In addition, IkBa and p105 are upregulated by NF-kB, which is thought to ensure a successful feedback, terminating the NF-kB signal eventually resulting in an efficient regulation mechanism. 9, 10 NF-kB-associated mediators, like certain cytokines and chemokines, play an important role in the onset and augmentation of various inflammatory diseases in the gastrointestinal tract. A deregulated function of NF-kB is associated with Crohn's disease and ulcerative colitis, as well as other inflammatory diseases like asthma and rheumatoid arthritis. [11] [12] [13] [14] Mucosal barrier injury, an important dose-limiting side effect of anticancer treatment, is defined and characterised by an increased villous atrophy and subsequently induced intestinal permeability. It is hypothesised that, in the onset of mucosal barrier injury, the release of cyto-and chemokines is crucial. 15, 16 In addition, DNA damage induced by anticancer therapy is known to activate NF-kB. 3, 17, 18 Therefore, the inhibition of NF-kB could be beneficial in the reduction of mucosal barrier injury.
However, it should be realised that NF-kB activation is essential for cell proliferation and cell survival. 11, 19, 20 Moreover, it has been postulated that NF-kB inhibition increases the susceptibility of various cancers to chemotherapeutic-or radiation-induced apoptosis. 21, 22 For instance, the blockade of NF-kB activity in prostate cancer cells inhibits angiogenesis, invasion and metastasis. In human ovarian cancer cells also an inhibition of tumorigenicity could be detected. 23, 24 This suggests that the inhibition of NF-kB during anticancer therapy may increase the susceptibility of both the transformed cancer cells and the nontransformed cells, that is, the intestinal epithelia, to anticancer treatment. Taking all these findings into account, it can be hypothesised that the inhibition of NF-kB might have positive as well as negative health effects during anticancer therapy.
A well-known NF-kB inhibitor is curcumin originating from powered rhizomes of the plant Curcuma longa Linn. Curcumin is known for its wide ranges of beneficial effects, such as antiinflammatory and cancer chemopreventing activities. 25 These activities include antioxidation, 26 suppression of c-jun/AP-1, 27 inhibition of prostaglandin biosynthesis 28 and inhibition of the activity and expression of the enzyme cyclooxygenase. 29, 30 A second NF-kB inhibitor is caffeic acid phenethyl ester (CAPE). It does not affect other transcription factors like AP-1 or Oct-1. 31 Furthermore, besides the inhibition of NF-kB, CAPE suppresses lipid peroxidation, 32 displays antioxidant activity, 33 inhibits ornithine decarboxylase, protein tyrosine kinase and lipoxygenase activities. 34 Both inhibitors could effectively be used in vivo to inhibit NF-kB activation during anticancer treatment.
The present study addresses the use of curcumin and its effects on the small intestine during methotrexate (MTX) treatment in rats. In addition, the inhibition of NF-kB by CAPE was investigated in the onset of mucosal barrier injury as a deleterious side effect of anticancer treatment, that is, chemotherapy.
Material and methods

Cells
The nontransformed small intestinal rat epithelial cell line (IEC-6, CRL-1592) was obtained from the ATCC (Rockville, MD, USA). Cells were cultured in Dulbecco's modified Eagle's medium adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 50 IU/ml penicillin, 50 mg/ml streptomycin and 10% foetal calf serum. Media and supplements were obtained from Gibco BRL (Breda, The Netherlands). The cell line was kept in a continuing culture in a humidified atmosphere at 371C and 5% CO 2 and was used in the experiments between passages 18 and 35.
Immunofluorescence localisation of NF-kB
For localisation of the NF-kB subunit, that is, p65, an immunofluorescence technique was used. For this technique, the IEC-6 cells were plated on a chamber slide system (Nunc, Invitrogen, Merelbeke, Belgium). Cells were stimulated for 24 h with 2.5 mg/ml of the chemotherapeutic agent arabinoside cytosine (Ara-C) (cytarabine; Sigma, Zwijndrecht, The Netherlands), with or without 0.25 mg/ml CAPE (Calbiochem, Darmstadt, Germany) or 2.5 mg/ml curcumin (ICN Biomedical, Zoetermeer, The Netherlands), both inhibitors of NF-kB. After fixation with 4% paraformaldehyde for 30 min, permeability of the cells was induced using 0.1% Triton X-100 (Sigma) and 0.5% Bovine Serum Albumin (BSA, Sigma) in phosphatebuffered saline (PBS) for 30 min. After washing the cells with PBS containing 0.1% Triton X-100 and 0.01% BSA, the cells were incubated with a-p65 (0.1 mg/ml mouse-anti-rat monoclonal antibodies (mAb), Santa Cruz Biotechnology, Heidelberg, Germany) for 1 h at room temperature, followed by incubation for 1 h with a secondary anti-mouse-FITC (Sigma, Goat antimouse IgG). After extensive washing with PBS, the slides were mounted with a water-based immu-mount (Shandon, Pittsburgh USA) and analysed using the KS300 image analysis software (Zeiss, Weesp, The Netherlands).
Quantification of NF-kB activation
IEC-6 cells were incubated with 2.5 mg/ml Ara-C or with 2.5 mg/ ml MTX in Petri dishes (Costar, Badhoevedorp, The Netherlands) and harvested at 0, 8, 16 and 24 h with cell lysis buffer containing 20 mM HEPES (pH 7.5), 350 mM NaCl, 20% glycerol, 1% Igepal-CA630, 1 mM MgCl 2 , 0.5 mM EDTA and 0.1 mM EGTA. In order to prevent protein degradation and additional NF-kB activation, the lysis buffer contained 0.2% PMSF and a protease inhibitor cocktail (Boehringer Mannheim, Germany). Additional plates of cells were coincubated with either 0.25 mg/ ml CAPE or 2.5 mg/ml or curcumin and harvested at 24 h. A total of 10 mg cell lysate was used for the detection of p65 binding to DNA using a TransAM NF-kB ELISA (Active Motive, Rixensart, Beligium). The method was performed according to the manufacturer's protocol. Briefly, 10 mg of total cell lysates were incubated for 1 h in 50 ml of binding buffer (4 mM HEPES (pH 7.5), 120 mM KCl, 8% glycerol, 1% BSA) in a 96-well plate precoated with the NF-kB consensus site (5 0 -GGGACTTTCC-3 0 ). 35 Only the activated (nuclear) NF-kB subunit p65 binding will be detected, since cytosolic NF-kB bound to IkB is unable to bind DNA. After washing with the supplied buffer, the wells were incubated for 1 h with 0.1 mg/ml a-p65 monoclonal antibody, followed by an incubation with the supplied horse radish peroxidase-conjugated antibody (0.2 mg/ml). Finally, the presence of activated p65 was visualised using 3,3 0 ,5,5 0 -tetramethylbenzidinesubstrate, and stopped with H 2 SO 4 , followed by detection at 450 nm.
Cellular viability
The metabolic activity of IEC-6 cells plated in 96-well plate was measured for the time periods as indicated in the figures with 2.5 mg/ml Ara-C or 2.5 mg/ml MTX in the presence or absence of the NF-kB inhibitors CAPE (0.25 mg/ml) or curcumin (2.5 mg/ml). After 4 h incubation at 371C with 50 ml tetrazolium salt 2,3-bis[2-methoxy-4-nitro-5-[(sulphenylamino)carbonyl]-2H-tetrazolium-hydroxide] (XTT) solution as provided in the kit from Boehringer Mannheim, the formation of the formazan dye by metabolically active cells was measured at 490 nm.
Flowcytometry
Cells were incubated for 48 h with 2.5 mg/ml Ara-C with or without 0.25 mg/ml CAPE or 2.5 mg/ml or curcumin in Petri dishes (Costar) and prepared for flowcytometry as described previously. 36 Briefly, after fixation using 250 ml 96% (À201C) ethanol for at least 30 min, cells were centrifuged at 41C for 5 min at 2000 r.p.m., and were subsequently washed twice with 1 ml PBS. For cellular DNA labelling, cells were incubated for 45 min at room temperature in the dark with 500 ml propidium iodide (5 mg/ml, Sigma) DNAse-free RNAse (0.05 mg/ml, Boehringer) solution. Finally, cells were analysed using a Flowcytometer (Coulter, Mijdrecht, The Netherlands).
RT-PCR
Total RNA was isolated from 2 Â 10 6 IEC-6 cells or 20 mg tissue using the RNeasy kit from Qiagen (Hilden, Germany) according to the manufacturer's protocol. The total RNA fractions were treated with 30 U DNAse (Qiagen) during isolation for 30 min at room temperature, to obtain pure samples of total RNA. Subsequently, mRNA was than converted to cDNA by incubating 1 mg total RNA for 45 min at 421C with 0.5 mg Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and 200 U SuperscripttII RNase H À Reverse Transcriptase, both obtained from Gibco BRL in the conditions described by the manufacturer. Finally, using specific primers for rat TNF-a and MCP-1 obtained from Biosource Inc (Nivelles, Belgium), PCR products were induced. The quantification of the PCR products separated on a 2% agarose gel was performed using a Lumi-imagert (Boehringer Mannheim, Germany).
MTX animal model
The animal experiments were approved by the Animal care and Ethics Committee (DEC Consult, The Netherlands), and were performed according to the UKCCCR guidelines. 37 Female Wag/ Rij rats (Charles River, Wiga, Germany), 8 weeks of age at the time of the first MTX injection with an average weight of 111.273.7 g, were used. The animals were housed in pairs in a conventional environment under controlled humidity and a 12:12-h-reversed light/dark cycle, with free access to chow and water. At 7 days before the first MTX injection, all rats were switched to a semisynthetic diet (Hope-farms, Woerden, The Netherlands) containing a constant amount of 1 mg/kg folic acid. At the same time, they were trained to expect to be given a supplement twice daily at 9:00 and 16:00 using a placebo containing 2.5% casein, 2.5% sucrose and strawberry vanilla flavour dissolved in water, which was added in addition to the normal chow. The placebo and semisynthetic diet were given to the animals until the end of the experiment. The dosage schedule of MTX treatment leading to intestinal damage and regeneration without causing death was obtained from pilot studies.
To investigate the onset of mucosal barrier injury in this MTX model, 20 rats were injected i.v. on day 0 with 20 mg/kg body weight MTX (Ledertrexate SP Forte, AHP Pharma Hoofddorp, The Netherlands), followed by a second MTX injection of 20 mg/ kg body weight 24 h later. A control group of four rats received 0.9% NaCl solution instead of MTX. The body weight of the animals was monitored daily. The animals were killed in groups of 4, that is, directly after the first MTX injection (day 0), and subsequently in 24 h periods until the last group was killed 96 h after the first MTX injection.
In order to investigate the effect of NF-kB inhibition, 24 rats (n ¼ 4 per group) were used, undergoing the same treatment as described above, of which two groups were supplemented with 2.5 mg/kg/day CAPE (n ¼ 8) or 2.5 mg/kg/day curcumin (n ¼ 8). These NF-kB inhibitors were added to the placebo and given in addition to normal chow starting one day before the first MTX injection, until the end of the experiment. In this experiment, the animals were killed on day 4 (96 h) for histopathology measurements, and on day 2 (48 h) for the analysis of cytokine and chemokine responses. All animals were killed under sedation using 2-3% isoflurane (Abbot Laboratories, Kent, UK), and segments of the small intestine were taken from the animals for (immuno-) histochemistry or mRNA analysis. All segments were carefully rinsed once with ice-cold PBS and frozen immediately in liquid nitrogen or were fixed in 4% paraformaldehyde (pH 7.4) (Sigma) for 16 h, dehydrated and embedded in paraffin.
Immunohistology
To examine histopathological changes in the intestine, 5 mm sections were cut, and rehydrated, before staining with 1 mg/ml Haematoxylin (Sigma) and 10 mg/ml eosin (Sigma). Histopathological changes were measured as absorption surface-distance ratios as described by Howart et al, 38 using an image analyses software (Zeiss, KS300 image analysis software). The effects were studied and analysed at a magnitude of 10 Â for each rat. At least 30 measurements per rat were performed without the knowledge of the treatment of the animal. Directly after rehydration, myeloperoxidase-positive (MPO þ ) cells were detected on similar slices and were visualised using 3,3 0 -diaminobenzidine staining tablets (Sigma) that were dissolved in water. The cells were counted at a magnitude of 60 Â in frames of 0.05 mm 2 . At least 30 measurements per rat were performed without knowledge of the treatment of the animal.
The localisation of TNF-a in the small intestine was performed on frozen sections (7 mm) using an acetone fixation, followed by the incubation with mouse anti-rat TNF-a (0.5 mg/ml mouse mAb, Santa Cruz Biotechnology) for 1 h. Thereafter, sections were incubated with 0.5 mg/ml anti-mouse IgG (Vector Laboratories, Brunschwig Chemie, Amsterdam, The Netherlands) for 1 h, followed by thorough washing with PBS. Using ABC complex and AEC substrate (Vector Laboratories), the final 'staining' was performed. After thorough washing, the slides were mounted with water-based immu-mount (Shandon, Pittsburgh, USA), and analysed using KS300 image analysis program (Zeiss).
Statistical analysis
The Student's two-tailed t-test was used to analyse differences in the morphology measurements, as well as the MPO þ cell influx between the control group not receiving MTX and the groups receiving MTX injections at the different time points as indicated. Similar analysis on morphology and MPO þ cell influx was carried out to observe significant differences between the MTX-treated rats receiving only placebo and the rats treated with MTX receiving either curcumin or CAPE. Same statistical analysis was performed on in vitro data. P-values o0.05 were considered to be statistically significant.
Results
To study the role of NF-kB on epithelial cell survival during chemotherapy treatment, first the activation of NF-kB was measured. Secondly, two different components were used to inhibit NF-kB, that is, curcumin and CAPE. The activation of NFkB in response to Ara-C as well as MTX has been studied using immunofluorescence labelling of p65, in the IEC-6 of rat origin. NF-kB translocation to the nucleus could be visualised after 8 h of incubation with 2.5 mg/ml Ara-C and 16 h after incubation with 2.5 mg/ml MTX (data not shown). In Figure 1 , the translocation of p65 to the nucleus after stimulation for 24 h with both cytostatic drugs is visualised. In addition, incubation with 0.25 mg/ml CAPE, a pharmaceutical NF-kB inhibitor, resulted in the inhibition of NF-kB activation during stimulation with 2.5 mg/ml Ara-C as well as during incubation with 2.5 mg/ml MTX (Figure 1d) . No fluorescence p65 labelling could be conducted with curcumin, because of its autofluorescence properties. Using a TransAM p65 detection assay (Active motive), the DNA binding of activated p65 in response to both cytostatics was quantitated (Figure 2 ). Incubation for 8 h with 2.5 mg/ml Ara-C results in a significantly (Po0.01) higher induction of NF-kB (0.29970.006) in comparison with an 8 h incubation of 2.5 mg/ml MTX (0.23970.016). Furthermore, the NF-kB activation induced with the incubation of 2.5 mg/ml MTX (0.42170.050) or 2.5 mg/ml Ara-C (0.499 Â 0.036) after 24 h 
Figure 1
Visualisation of chemotherapy-induced NF-kB activation (ie nuclear localisation of NF-kB). For immunofluorescence localisation of p65 IEC-6 (a) were incubated with 2.5 mg/ml MTX (b) or 2.5 mg/ ml Ara-C (c) with or without 0.25 mg/ml CAPE (d) for 24 h. Cells were fixed and NF-kB was detected using anti-p65 mAb, followed by visualisation with FITC (green).
Role of curcumin and inhibition of NF-jB mucosal barrier injury B van't Land et al could be blocked with the addition of either 0.25 mg/ml CAPE or 2.5 mg/ml curcumin. Cellular viability of the nontransformed IEC-6 incubated with Ara-C as well as with MTX decreased in a dose-(data not shown) and time-dependent manner (Figure 2b ). Not until 48 h of incubation with 2.5 mg/ml MTX or 2.5 mg/ml Ara-C, a significant reduction (Po0.05) in cellular viability could be detected of 23710% and 76711%, respectively. Since both MTX and Ara-C induced the activation of NF-kB ( Figure 2) and Ara-C gave a more pronounced effect on cell viability, Ara-C was used to study the effect of NF-kB activity on cell viability and cell death. The effect of NF-kB inhibition by CAPE or curcumin, on the induction of cell death by Ara-C, was tested using flowcytometry. The induction of cell death by 2.5 mg/ml Ara-C (28.071.6%) as shown in Figure 3a and b is characterised by a reduction of cells in the G1 phase. As shown in Figure 3c , the fraction of cell death induced by Ara-C was increased significantly (Po0.001) to 45.074.0% when coincubated with 0.25 mg/ml CAPE, indicating an increased susceptibility of the IEC-6's to Ara-C-induced cell death. However, when NF-kB inhibition was achieved by coincubation with 2.5 mg/ml curcumin, the cell death fraction was reduced significantly (Po0.001) to 19.470.9%. Cellular viability as measured using the XTT analysis as described above showed similar effects (Figure 3d ). The cellular viability of IEC-6 cells after Ara-C treatment (34.272.3%) was significantly rescued (Po0.05) to 50.174.2% when cells were coincubated with 2.5 mg/ml curcumin, but was significantly (Po0.05) reduced to 23.275.5% when coincubated with 0.25 mg/ml CAPE. This indicates that although both curcumin and CAPE inhibit NF-kB effectively, the effect on the susceptibility to Ara-C-induced cell death and viability differs in these nontransformed IEC-6's.
In addition to the NF-kB activation by Ara-C, an induction varying from 18-to 129-fold mRNA specific for TNF-a and MCP-1, respectively, was observed after 16 h of incubation with 2.5 mg/ml Ara-C in a time-dependent manner (Figure 4a) . 
Figure 3
Inhibition of NF-kB by CAPE, but not by curcumin, increases the susceptibility of IEC-6 cells to Ara-C-induced cell death. The percentage of cell death is detected by flowcytometry analysis of propidium iodide-labelled IEC-6 cells incubated with 2.5 mg/ml Ara-C, with or without 0.25 mg/ml CAPE or 2.5 mg/ml curcumin. A total of 10 000 cells were counted and divided into four sections representative of their DNA content, as indicated in (a) (control cells) and (b) (Ara-C-treated cells). The bars (c) show the% of cell death as mean7s.d. of three independent experiments. nnn Significant differences in the apoptotic fraction (Po0.001). Cellular viability was measured using the XTT assay (d). IEC-6 cells were cultured with 2.5 mg/ml Ara-C with or without 0.25 mg/ml CAPE or 2.5 mg/ml curcumin at 72 h. The bars show mean7s.d. of cellular viability as% of control cells not treated with either cytostatic drugs or NF-kB inhibitors from a representative experiment.
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Treatment with MTX resulted in a comparable induction of both TNF-a and MCP-1 (data not shown). The production of TNF-a and MCP-1 seen in response to Ara-C as well as MTX (data not shown) was reduced, although to a different extent, when IEC-6 cells were incubated with 2.5 mg/ml curcumin, indicating a functional inhibition of Ara-C-induced NF-kB activation by curcumin (Figure 4b) .
To determine the effect of curcumin supplementation on chemotherapy mucosal barrier injury, a well-described rat model for MTX-induced intestinal damage was used. 39 First of all, NF-kB activation and its mediators were determined in the onset of mucosal barrier injury. CAPE was used in these studies as a second NF-kB inhibitor known to increase the susceptibility to chemotherapy-induced cell death. In accordance with in vitro data as depicted in Figure 4 on IEC-6 cells, an induction of Figure 4 Inhibition of NF-kB by curcumin functionally reduces Ara-C-induced cytokine and chemokine response. IEC-6 cells were cultured in the presence of 2.5 mg/ml Ara-C and mRNA was isolated at the time point indicated for RT-PCR (a). (b) Represents IEC-6 cells, which were incubated with 2.5 mg/ml Ara-C with or without 2.5 mg/ml curcumin for 24 h. PCR products specific for TNF-a and MCP-1 were normalised to b-actin expressions. The bars represent mean7s.d. of three independent experiments as fold induction compared to cells cultured in the absence of Ara-C. 
Figure 5
MTX-induced damage of the small intestine is associated with cytokine and chemokine responses, localised in the crypt cell compartment of rats. A small intestinal damage was induced using two injections of 20 mg/kg methotrexate. The induction of PCR products from mRNA specific for TNF-a and MCP-1 in the duodenum normalised for b-actin are shown as fold induction compared to duodenum values of rats at day 0 (a). Bars represent mean7s.d. of three independent experiments. (b) Shows Cross-sections of the duodenum of rats nontreated or treated with MTX, respectively. The sections were stained for the presence of TNF-a using specific mAb's and AEC substrate, which gives a red colouring. The sections were counterstained with haematoxylin, and pictures of representative area were carried out at a magnification of Â 40 using KS 300 (Zeiss). At time points indicated, histopathology (c), MPO þ cell influx (d) were measured in the duodenum of rats (n ¼ 4 per group) treated with MTX on 2 consecutive days with a 24 h interval. For each rat, histopathology was measured at least in three different cross-sections at a magnification of Â 10. Bars show mean% of control7s.e.m. for four rats per group receiving MTX and killed at the time points indicated. For MPO þ cell influx over 30 fields from 0.05 mm 2 were analysed per animal, at a magnification of Â 60. Bars show mean7s.e.m. of four rats per group. In both figures, statistical differences between the control group not receiving MTX and the groups receiving MTX are indicated with n (Po0.05), nn (Po0.01) and nnn (Po0.001).
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17-to 30-fold of rat-specific mRNA for TNF-a and MCP-1 could be detected in vivo in the duodenum as soon as 24 h after the first MTX injection (Figure 5a ). Also, an MTX-induced cytokine and chemokine response could be detected in the jejunum and to a lesser extent in the ileum (data not shown). No data were obtained in vivo of earlier time points to establish a dose-and time-dependent relation of the cytokine and chemokine mRNA induction. To locate the cells responsible for the MTX-induced TNF-a production, an immuno-histological analysis on frozen sections was performed. As shown in Figure 5b , a specific increase in TNF-a was found in the crypt cell area in response to the MTX treatment, indicating that the epithelial cells in this region are responsible for the induction of TNF-a. For further validation of the model also other intestinal damage parameters were analysed. The absorption surface and therefore histopathological effects of the duodenum were significantly reduced to 3876% (Po0.001) starting on day 3 (Figure 5c ), followed by a significant reduction in the jejunum (Po0.05) on day 4 (data not shown). Intestinal damage is often associated with the influx of active MPO þ granulocytes. Moreover, in this model of MTX-induced intestinal damage, an influx of MPO þ cells was observed (Figure 5d ). In the duodenum, already on day 2, a significant increase of 13.571.1 MPO þ cells/0.05 mm 2 (Po0.001) is observed, followed by a significant induction in the jejunum (Po0.05) on day 3 (data not shown).
Animals (four per group) were supplemented daily with 2.5 mg/kg CAPE or 2.5 mg/kg curcumin to establish the effect of these components on the onset of mucosal barrier injury. The supplementation started 24 h before the first MTX injection until the end of the experiment. To confirm whether supplementation with CAPE functionally inhibits NF-kB activation in the small intestine, sections were analysed for the induction of mRNA specific for TNF-a and MCP-1, as well as the influx of MPO þ cells was measured. As shown in Figure 6a , CAPE functionally reduces the NF-kB-associated mediators analysed in the duodenum. The induction of TNF-a and MCP-1 seen in the duodenum of rats receiving only MTX was reduced 3.7 and 3.2 times, respectively, when the animals were supplemented with CAPE. In accordance with the inhibition of the NF-kB mediators, an inhibition of MPO þ cell influx could be detected in rats when supplemented with CAPE (Figure 6d) . However, no inhibition on the influx of MPO þ cells could be detected in the rats receiving curcumin. Figure 6c shows the effect of CAPE and curcumin in vivo on the onset of villous atrophy. A significant re-establishment of the villous morphology could be detected in Figure 6 Supplementation with CAPE or curcumin did not increase MTX-induced villous atrophy and MPO þ cell influx. For establishment of functional inhibition of cytokine and chemokine induction in vivo mRNA isolated from duodenum at day 2 after the first MTX injection and were analysed using semiquantitative RT-PCR for TNF-a and MCP-1 (a). Bars represent normalised arbitrary units as fold induction compared to rats not receiving MTX, from the specific PCR products as indicated in the figure. Mean7s.d. is displayed from two rats per group. For the analysis of intestinal histopathology (c) and MPO þ cell influx (d), the rats were killed 4 days after the first MTX injection. The rats (n ¼ 4 per group) were treated with MTX on 2 consecutive days, and supplemented with 2.5 mg/kg/day CAPE or 2.5 mg/kg/day curcumin during treatment. Intestinal histopathology was visualised using haematoxylin staining on deparaffinised sections, bars reflect means7s.d. as percentage of control from rats not receiving MTX treatment. MPO þ cells were visualised using 3,3 0 -diaminobenzidine staining on deparaffinised sections; over 30 fields from 0.05 mm 2 was analysed per rat. Bars reflect means7s.d. from four rats per group in both figures. Figure 5b shows the body weight measured as the percentage of weight at day 0 representing mean7s.d. of four rats. n Significant differences between MTX-treated rats receiving placebo and MTX-treated rats supplemented with CAPE or curcumin.
the duodenum when supplemented with curcumin, but not when supplemented with CAPE.
The effect of MTX treatment as well as the supplementation of CAPE or curcumin on the body weight of the animals during the experiment is shown in Figure 6b . The treatment of MTX resulted in a reduction in body weight of 5%, which could partly be diminished by supplementation with curcumin. Moreover, no increased signs of the intestinal damage, that is, weight loss, morphological changes or MPO þ cell influx could be detected in any region of the small intestine of rats supplemented with either CAPE or curcumin during treatment with MTX. Furthermore, the dosage of curcumin in vivo had been increased up to 125 mg/kg and still no toxicity was observed in the small intestine (data not shown).
Discussion
The activation of NF-kB is not only associated with the induction of inflammatory reactions but also plays an important role in the survival of cells under various cellular stresses. 1, 40 It has been hypothesised that through the activation of NF-kB, both these processes might modulate the onset of mucosal barrier injury. In more detail, inhibition of the inflammatory responses during chemotherapy might reduce the onset of mucosal barrier injury, whereas inhibition of cell survival regulated by NF-kB might increase villous atrophy, the doselimiting side effects of chemotherapy treatment. Therefore, the inhibition of NF-kB by, for instance, curcumin, might have positive as well as negative health effects during anticancer therapy. In addition, CAPE was used as a second NF-kB inhibitor to study the possible role for NF-kB in the onset of intestinal atrophy during chemotherapy.
As shown in this study, both the cytostatic drugs MTX and Ara-C induced NF-kB activation in IEC-6 cells, which was followed by the production of proinflammatory cytokines and chemokines as well as the induction of cell death. Also in vivo, the production of proinflammatory cytokines and chemokines after MTX injection could be measured on both the mRNA and protein levels. The NF-kB-related TNF-a production could be especially detected in the crypt cells, suggesting that cytokines and chemokines are produced, in particular, by the epithelial stem cells in response to MTX treatment. These results demonstrate the production of proinflammatory cytokines and the activation of NF-kB after chemotherapy in vitro and indirectly in vivo. This is in accordance with the hypothesis that chemotherapy induces a proinflammatory response in the intestine as suggested previously. 15, 16 Besides a direct effect of MTX-induced NF-kB activation on the induction of an inflammatory response in the epithelium as shown in Figures  5a,b and 6a , the activation of NF-kB might also be related in a later stage to barrier destruction. This might subsequently lead to the influx of bacteria, resulting in an indirect cytokine response. However, this will not be related to the early onset of mucosal barrier injury.
A significant activation of NF-kB and subsequently the NF-kBregulated cytokine production could be measured after 16 h of incubation with either MTX or Ara-C, which is in contrast with the finding by others. These previous results indicate that MTX inhibits TNF-a-induced NF-kB activation. 41 This discrepancy in findings is probably due to differences in the incubation periods used. The TNF-a-induced NF-kB activation could only effectively be inhibited when preincubation with MTX, and thus pyrimidine pool depletion was established before TNF-a incubation. This indeed might occur before DNA-damageinduced NF-kB activation is achieved. Furthermore, TNF-ainduced NF-kB activation is receptor mediated, whereas early DNA-damage-induced NF-kB activation is not. This indicates different routes of activation. The activation of NF-kB might be related to this induction of cell death. This is, however, probably not the case, since cellular viability did not decrease significantly until 48 h of incubation with either Ara-C or MTX.
With respect to the role of NF-kB and cytokines on cell survival of epithelial cells in the intestine after chemotherapy treatment, differences between the inhibitors used were obtained in both IEC-6 cells and MTX-treated rats. The inhibition of NF-kB in IEC-6 cells by CAPE resulted in an increased susceptibility of IEC-6 cell to Ara-C-induced cell death, whereas inhibition of NF-kB by curcumin resulted in decreased susceptibility to Ara-C-induced cell death (Figure 3 ). Both agents did inhibit NF-kB activation in IEC-6 cells after incubation with Ara-C and MTX (Figure 2) . The difference between both agents may in part be due to the fact that inhibition of NF-kB by curcumin and CAPE are achieved at two different levels. Curcumin inhibits NF-kB through the suppression of phosphorylation and degradation of IkBa. [42] [43] [44] CAPE modifies the NF-kB protein so that it can no longer bind to DNA without any effect on IkBa phosphorylation or IkBa degradation. 31, 45 Perhaps, by inhibiting the phosphorylation and degradation of IkBa, degradation of other proteins are also inhibited, whereas the inhibition of NFkB binding to DNA could induce apoptosis. The difference in the NF-kB inhibitor pathway and response to chemotherapyinduced cell death is currently under investigation. The differences between CAPE and curcumin cannot be explained by differences in cytokine production inhibition. Both agents inhibited the production of cytokines (Figure 4 ). In addition, cytokines itself did not influence Ara-C-induced cell death or viability in IEC-6 cells, because addition of cytokines or cytokine-specific antibodies to IEC-6 cells during incubation with Ara-C did not have any effect on the induction of cell death (data not shown). Irrespective of its mechanism, in the in vitro study with IEC-6 cells, it was shown that curcumin inhibits the Ara-C-induced cell death (Figure 3 ). This is in contrast with the previously described results. Prostate cancer cells become more susceptible to cytostatic drug-induced apoptosis when incubated with curcumin. 21 Perhaps, differences between the transformed and nontransformed cells account for these different findings.
To study the effect of curcumin supplementation and the inhibition of NF-kB in vivo on chemotherapy-induced mucosal barrier injury, both CAPE and curcumin were tested in an animal model, wherein rats were treated with MTX. The inhibition NFkB activation using curcumin as shown by Sugimoto et al, 46 in addition to our data, is effective throughout the entire gastrointestinal tract. Although the inhibition of NF-kB by CAPE did increase susceptibility of IEC-6 cells to Ara-C-induced cell death, supplementation with CAPE did not increase the small intestinal damage induced by MTX in vivo. Supplementation of CAPE, however, did show an inhibition on the MPO þ cell influx in the duodenum, which correlates with the reduced MCP-1 response (Figure 6 ). This again suggests an effective NFkB inhibition by the supplementation of CAPE, since both TNF-a and MCP-1 are NF-kB regulated. The latter result might suggest that the influx of MPO þ cells has only a minor effect on the onset on mucosal barrier injury. Despite the fact that curcumin reduced in vitro the cytokine response, in vivo supplementation with curcumin did not have any effect on the influx of MPO þ cells ( Figure 6 ). Since supplementation of curcumin shows a significant protection on villous atrophy, this result is in contrast with the in vitro data, where curcumin-inhibited chemotherapy induced cell death, at the same concentration at which the activation of NF-kB and subsequently the cytokine and chemokine production was inhibited. In summary, a reduction of villous atrophy was achieved without the inhibition of the inflammatory response as measured by MPO þ cell influx. This again suggests a minor role for the inflammatory response in the onset of mucosal barrier injury. The results also directly indicate that the use of CAPE and curcumin does not stimulate the onset of mucosal barrier injury. Since both compounds do not worsen villous atrophy, this also implies that the use of NF-kB inhibitors in order to increase the susceptibility of cancer cells to cytostatic drug-induced cell death does not have a negative effect on the onset of mucosal barrier injury. However, since the effects in vitro using curcumin and CAPE does have a detrimental effect on chemotherapy-induced cell death, caution should be exercised when extrapolating these data to the clinic, assuming that the use of NF-kB inhibitors in the clinic to sensitise cancer cells to the chemotherapy treatment moves forward. 47, 48 However, due to the differences in pathways to inhibit NF-kB, like with curcumin and CAPE, and also using proteasome inhibitors like PS-341, 47, 48 the effect on the deleterious side effects normally seen during anticancer treatment will need extra attention during the trials.
It should be realised that it is not known so far as to whether the NF-kB inhibition obtained by CAPE and curcumin in the doses tested in this study will increase the susceptibility of various cancers in vivo to cytostatic drug-induced cell death. In mice, a dosage of 0.2% w/v curcumin in the diet inhibited the development or promotion/progression to disease stages of azoxymethane-induced colonic adenocarcinomas in mice. 25, 49 Moreover, a 64% reduction in adenoma formation in the intestine of Min-mice, which harbour genetic mutation similar to the predisposition to development of adenomatous polyposis in humans, was seen using 0.1% curcumin. 50 Taking into account the fact that rats eat approximately 5 g/day, suggests that with 0.2% curcumin in the diet an effective concentration of 10 mg/day is required for the chemopreventive properties of curcumin. The highest concentration of curcumin tested in vivo in our studies was 12.5 mg/day without signs of intestinal toxicity. An effective dosage of curcumin to inhibit NF-kB systemically, however, remains to be elucidated in humans.
In conclusion, MTX-induced NF-kB activation in epithelial cells resulted in the production of proinflammatory cytokines and chemokines both in vitro and in vivo, which subsequently could be reduced by curcumin and CAPE. Moreover, in vivo supplementation of both curcumin and CAPE did not increase susceptibility to MTX-induced small intestinal damage.
